April 13, 2018 / 6:13 AM / in 6 months

BRIEF-Mauna Kea Cellvizio Demonstrates Superior Identification Of Patients At Risk For Esophageal Cancer

April 13 (Reuters) - MAUNA KEA TECHNOLOGIES SAS:

* MAUNA KEA TECHNOLOGIES’ CELLVIZIO® DEMONSTRATES SUPERIOR IDENTIFICATION OF PATIENTS AT RISK FOR ESOPHAGEAL CANCER COMPARED TO CURRENT DIAGNOSTIC STANDARD

* RESULTS FROM NEW CLINICAL STUDY THAT ENROLLED 172 PATIENTS AT 8 NON-ACADEMIC CENTERS IN UNITED-STATES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below